Beovu met its key endpoints in a phase 3 study investigating safety and efficacy in the treatment of diabetic macular edema, according to a Novartis press release.
The KITE study demonstrated the noninferiority of Beovu (brolucizumab 6 mg) vs. aflibercept 2 mg in mean change in best corrected visual acuity at 1 year. In addition, Beovu demonstrated “superior” improvement vs. aflibercept in change of central subfield thickness from week 40 through week 52. The Beovu safety profile was comparable to aflibercept, with equivalent intraocular inflammation rates.
KITE is ongoing and will